The Senate approved a handful of amendments by unanimous consent on Wednesday (see below), and will hold about a dozen votes before coming to the final bill. The legislation, S. 3187, is generally non-controversial, and would reauthorize and extend a user-fee program that drug and medical device industry groups support as a way of speeding up the FDA approval process.

ADVERTISEMENT
Once the bill is passed, the Senate will turn to a much more contentious bill, S. 2343, the Stop Student Loan Interest Rate Hike Act. The Democratic bill extends low interest rates on new, federally backed student loans for another year, and pays for it by subjecting more high-earners' income to the payroll tax.

As part of a deal announced Wednesday, Republicans won the right to have a vote on their alternative plan, which would terminate a preventive health fund created in 2010.

But approval of both the GOP alternative and the Democratic bill will need 60 votes to pass. Because each party seems to genuinely hate the other's bill, the votes might well be a setup for partisan finger-pointing once both fail, which will at least give the parties something to talk about over the long Memorial Day weekend.

The Senate should also approve a 60-day extension of the National Flood Insurance Program at some point today. Senate Majority Leader Harry ReidHarry ReidThe Hill's 12:30 Report Emanuel flips the bird when asked about 2020 Feinstein after dinner with Clinton: She has 'accepted' her loss MORE (D-Nev.) said Wednesday that he would agree to tackle a longer-term reform bill once the Senate returns from its Memorial Day week off.

Also up today, a likely vote on a bill to extend the National Flood Insurance Program (NFIP) for 60 days, also part of Wednesday's announcement.

In a unanimous-consent vote Wednesday, the Senate approved H.R. 4097, the John F. Kennedy Center Reauthorization Act, and the following six amendments to the FDA bill, from:

• Sen. Ben CardinBen CardinDems fear Trump undermining US stature Aide: Trump invited Philippine leader to WH Dem senator: Hold hearing on Russian interference in election MORE (D-Md.), to ensure that adequate information is disseminated to healthcare providers and payers about the potential benefits and risks of medical products on all patient populations, particularly underrepresented sub-populations, including racial subgroups;

• Cardin, to require the commissioner of Food and Drugs to report to Congress on issues with respect to small businesses;

• Sen. Chuck GrassleyChuck GrassleyMnuchin, Price meet with GOP senators Business groups express support for Branstad nomination 10 no-brainer ways to cut healthcare costs without hurting quality MORE (R-Iowa), to provide employee protections for the Commissioned Corps of the Public Health Service Act;

• Grassley, to provide deadlines for the issuance of certain regulations and to require a GAO report on the implementation of the clinical trial registration and reporting requirements under the Public Health Service Act;

• Sen. Joe ManchinJoe ManchinHouse GOP made call on miners benefits Week ahead in defense: Anticipation builds for State pick; Pentagon chief's last trip abroad Manchin urging colleagues to block funding bill as shutdown looms MORE (D-W.Va.), to reclassify the pain reliever hydrocodone under the Controlled Substances Act; and

• Sen. Jack ReedJack ReedBudowsky: Did Putin elect Trump? This Week in Cybersecurity: Dems press for information on Russian hacks A Cabinet position for Petraeus; disciplinary actions for Broadwell after affair MORE (D-R.I.), to make effective the proposed rule of the Food and Drug Administration relating to sunscreen drug products.